tiprankstipranks
Trending News
More News >
Cogent Biosciences (COGT)
NASDAQ:COGT
US Market
Advertisement

Cogent Biosciences (COGT) AI Stock Analysis

Compare
599 Followers

Top Page

COGT

Cogent Biosciences

(NASDAQ:COGT)

Rating:37Underperform
Price Target:
Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.
Positive Factors
Clinical Trial Results
Recent top-line results for bezuclastinib’s SUMMIT trial in non-advanced systemic mastocytosis was well-received, propelling Cogent up 69%.
Market Opportunity
ASM could represent a significant underappreciated opportunity for Cogent to capture the majority of the market share and also expand the addressable market beyond that served by Ayvakit.
Regulatory Progress
Cogent intends on submitting a New Drug Application (NDA) to the FDA for bezuclastinib by end-2025.
Negative Factors
Competitive Concerns
The use of bezu might still be restricted in patients who don't adequately respond to Ayvakit based on the safety profile which will likely result in monitoring requirements.
Market Competition
Maintain HOLD rating based on the overall outlook on SM market that is believed will likely be dominated by Ayvakit.

Cogent Biosciences (COGT) vs. SPDR S&P 500 ETF (SPY)

Cogent Biosciences Business Overview & Revenue Model

Company DescriptionCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyCogent Biosciences makes money primarily through the development and commercialization of its precision therapies. The company generates revenue by advancing its drug candidates through clinical trials, securing regulatory approvals, and eventually launching these products into the market. Revenue streams include potential sales of approved therapies, milestone payments, and royalties from partnerships with larger pharmaceutical companies who may assist in the distribution and marketing of their products. Significant partnerships with other biotech firms and research institutions may also contribute to earnings by sharing resources, expertise, and financial support in the development of their therapies.

Cogent Biosciences Financial Statement Overview

Summary
Cogent Biosciences faces significant financial challenges with no recent revenue, substantial operating losses, and consistent net losses. The strong equity position is overshadowed by negative operating and free cash flows, indicating a reliance on external financing and heightened financial vulnerabilities.
Income Statement
20
Very Negative
Cogent Biosciences has experienced declining revenue over the years, with no recorded revenue in recent periods. Despite a high gross profit in earlier years, recent operating losses have been substantial, leading to negative EBIT and net income. The absence of revenue growth and consistent net losses indicate a challenging profitability environment.
Balance Sheet
35
Negative
The company's balance sheet shows a strong equity position with a high equity ratio, indicating limited financial leverage. However, persistent negative net income has impacted equity growth. Despite a relatively low debt-to-equity ratio, the lack of revenue generation poses a risk to financial stability.
Cash Flow
30
Negative
Cogent Biosciences has consistently negative operating and free cash flows, which raises concerns about long-term sustainability. While financing activities have historically supported liquidity, the reliance on external funding and absence of positive cash flow from operations suggest financial vulnerabilities.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.007.87M
Gross Profit0.00-3.59M-5.88M-147.00K7.85M
EBITDA-275.94M-205.86M-134.36M-75.40M-34.57M
Net Income-255.86M-192.41M-132.64M-71.81M-66.45M
Balance Sheet
Total Assets327.90M313.44M300.81M232.09M250.92M
Cash, Cash Equivalents and Short-Term Investments287.08M265.71M259.28M219.68M242.19M
Total Debt17.47M18.85M19.65M3.15M5.21M
Total Liabilities71.61M55.63M45.08M17.91M16.25M
Stockholders Equity256.29M257.80M255.74M214.18M234.67M
Cash Flow
Free Cash Flow-208.36M-156.42M-125.50M-60.48M-35.85M
Operating Cash Flow-207.79M-153.62M-118.64M-58.76M-35.85M
Investing Cash Flow38.28M-97.82M-124.72M-1.72M8.42M
Financing Cash Flow214.45M163.54M163.56M37.98M232.20M

Cogent Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.45
Price Trends
50DMA
7.57
Positive
100DMA
6.70
Positive
200DMA
8.00
Positive
Market Momentum
MACD
1.50
Negative
RSI
85.47
Negative
STOCH
78.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Positive. The current price of 12.45 is above the 20-day moving average (MA) of 9.93, above the 50-day MA of 7.57, and above the 200-day MA of 8.00, indicating a bullish trend. The MACD of 1.50 indicates Negative momentum. The RSI at 85.47 is Negative, neither overbought nor oversold. The STOCH value of 78.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COGT.

Cogent Biosciences Risk Analysis

Cogent Biosciences disclosed 50 risk factors in its most recent earnings report. Cogent Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We have experienced significant growth and expect to continue to expand our company to support research, development and future commercial capabilities and may face challenges in managing our growth. Q4, 2024
2.
Information obtained from expanded access studies may not reliably predict the efficacy of our future product candidates in company-sponsored clinical trials and may lead to adverse events that could limit approval. Q4, 2024
3.
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected. Q4, 2024

Cogent Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$2.11B13.9924.71%20.62%14.08%
64
Neutral
$1.86B-5.78%25.50%64.63%
56
Neutral
$1.93B-31.34%-54.85%-79.25%
56
Neutral
$2.17B-38.04%-82.38%-164.76%
52
Neutral
$7.46B-0.04-63.82%2.49%16.43%<0.01%
43
Neutral
$2.10B-23.34%-14.19%
37
Underperform
$2.04B-84.04%-2.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
COGT
Cogent Biosciences
12.37
3.20
34.90%
IDYA
IDEAYA Biosciences
23.63
-18.58
-44.02%
BEAM
Beam Therapeutics
22.16
-7.65
-25.66%
IRON
Disc Medicine
60.94
16.38
36.76%
HRMY
Harmony Biosciences Holdings
37.22
4.40
13.41%
IMCR
Immunocore Holdings
37.15
-2.43
-6.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025